OTTAWA, CANADA, October 29, 2025 – Genomadix (genomadix.com), a global leader in point-of-need precision medicine diagnostics, announced today that Hollie Huff, Ph.D. has been appointed the company’s new Chief Executive Officer. Hollie succeeds Steve Edgett, who will transition into a new strategic role within the company focused on partnerships and growth initiatives.

Ms. Huff brings over 20 years of leadership experience in the medical technology and diagnostics sectors at companies such as QuidelOrtho, Siemens Healthineers, Abbott and others. She has a proven track record of leadership and execution in business development, corporate strategy and M&A. She joins Genomadix at a pivotal time as the company advances its precision medicine diagnostics portfolio and broadens its commercial presence in global healthcare markets.

“I’m honored to join Genomadix at such an exciting stage of its journey,” said Hollie Huff, CEO of Genomadix. “Genomadix has built a strong foundation of innovation in rapid genetic testing to guide critical therapeutic decisions. I look forward to leveraging that momentum to advance our commercial growth and reinforce Genomadix’s leadership in precision medicine and life-saving diagnostics.”

Outgoing CEO Steve Edgett expressed his support for the leadership transition. “It has been a privilege to lead Genomadix through a period of incredible progress, including achieving regulatory clearances and commercial launch of our flagship CYP2C19 test and expanding our technology platform,” said Edgett. “Hollie’s leadership and experience make her the ideal person to guide Genomadix into this next stage. I’m excited to continue contributing to our mission in a new role and supporting Hollie as she takes the helm.”

Under Edgett’s leadership, Genomadix has achieved significant accomplishments, including FDA clearance in the United States for its Genomadix Cube™ CYP2C19 System, CE marking in Europe and Health Canada Medical Device Licence. With Huff’s appointment, the company aims to build on its strong foundation to expand its commercial reach and become the world leader in rapid precision medicine diagnostics.

About Genomadix
Based in Ottawa, Canada, Genomadix Inc. is a pioneer in rapid real-time qPCR technology. The Genomadix Cube™ is a molecular diagnostic instrument capable of performing tests for precision medicine genotyping on a sample-to-result platform. Its portable size, ease of use, and on-demand processing capability enable users to generate time-critical results in approximately one hour. Genomadix’s flagship rapid CYP2C19 genotyping test is used as an aid in therapeutic decisions in stroke, acute coronary syndrome as well as other conditions. The Cube platform is also available as an open platform (CubeX) that can be used to design, develop, and run any qPCR test for research or product development purposes. Applications of the Genomadix Cube technology include, but are not limited to, precision medicine, clinical diagnostics, and environmental testing.
For more information, visit www.genomadix.com.

Media contact:
Tara Linseman, Sr. Manager of Product Management
media@genomadix.com | +1-613-228-7756